Showing results (751-760 of 881) with videos related to
Sort By:
Pageof 89
Hepatology (Baltimore, Md.)|April 8, 2015
Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failedStanislas Pol, Mark S Sulkowski, Tarek Hassanein, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 6, 2024
Effects of Food Insecurity on Hepatic Steatosis and Fibrosis in People With HIVAni Kardashian, Audrey Lloyd, Eduardo Vilar-Gomez, et al.Hepatology (Baltimore, Md.)|May 13, 2015
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trialsSaleh A Alqahtani, Nezam Afdhal, Stefan Zeuzem, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2021
Evolution of Fatty Liver Disease and Relationship With Lipoproteins and Clinical Outcomes in Hepatitis B/Human Immunodeficiency Virus CoinfectionMandana Khalili, Wendy C King, David E Kleiner, et al.Hepatology (Baltimore, Md.)|March 19, 2013
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trialMark S Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 9, 2008
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis CDavid R Nelson, Vinod Rustgi, Vijayan Balan, et al.Open Forum Infectious Diseases|May 8, 2026
Non-Hispanic Black Persons With HIV Have a Lower Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease and Clinically Significant Fibrosis Compared to Non-Hispanic White and Hispanic IndividualsTinsay A Woreta, Samer Gawrieh, Laura A Wilson, et al.Antiviral Research|June 11, 2013
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokineticsEric Lawitz, Mark Sulkowski, Ira Jacobson, et al.Journal of Viral Hepatitis|March 4, 2024
Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugsMark S Sulkowski, Anthony Martinez, Gia L Tyson, et al.Journal of Viral Hepatitis|December 24, 2017
Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infectionM S Sulkowski, J J Feld, E Lawitz, et al.Pageof 89